Pacira Biosciences Inc
NASDAQ:PCRX
Pacira Biosciences Inc
Operating Income
Pacira Biosciences Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Pacira Biosciences Inc
NASDAQ:PCRX
|
Operating Income
$87.3m
|
CAGR 3-Years
13%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$24.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$10.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-5%
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$11.3B
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
See Also
What is Pacira Biosciences Inc's Operating Income?
Operating Income
87.3m
USD
Based on the financial report for Dec 31, 2023, Pacira Biosciences Inc's Operating Income amounts to 87.3m USD.
What is Pacira Biosciences Inc's Operating Income growth rate?
Operating Income CAGR 5Y
38%
Over the last year, the Operating Income growth was 23%. The average annual Operating Income growth rates for Pacira Biosciences Inc have been 13% over the past three years , 38% over the past five years .